

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



丽珠医药
LIVZON

麗珠醫藥集團股份有限公司

LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

PRELIMINARY ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR 2021

This announcement is made pursuant to Rule 13.09 (2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and the Inside Information Provisions (as defined by the provisions of Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571) of the Laws of Hong Kong by Livzon Pharmaceutical Group Inc. 麗珠醫藥集團股份有限公司 (the "Company", together with its subsidiaries, the "Group").*

The Company and all members of the board of directors guarantee that the information stated in this announcement is true, accurate and complete and does not contain any false representation, misleading statement or material omission.

Important: the financial data for the year 2021 set out in this announcement represents figures of preliminary estimations only and has not been audited by an auditing firm. As a result, differences may be found between the data below and the definitive financial data disclosed in the 2021 Annual Report. Investors are advised to be cautious about investment risks involved.

I. PRELIMINARY RESULTS FOR THE PERIOD

1. Period for the preliminary estimated results: 1 January 2021 to 31 December 2021
2. Preliminary estimated operating results: increase over the corresponding period last year

Item	Current reporting period	Corresponding period last year
Net profit attributable to the shareholders of the listed company	Profit: approximately RMB1,714.9104 million – RMB1,886.4014 million	Profit: RMB1,714.9104 million
	Increased by approximately 0% – 10% as compared to the corresponding period last year	
Net profit attributable to the shareholders of the listed company after deducting the extraordinary gains or losses	Profit: approximately RMB1,574.7043 million – RMB1,717.8593 million	Profit: RMB1,431.5494 million
	Increased by approximately 10% – 20% as compared to the corresponding period last year	
Basic earnings per share (RMB/share)	Profit: approximately RMB1.83 – RMB2.02 per share	Profit: RMB1.83 per share

II. COMMUNICATION WITH THE ACCOUNTING FIRM

Regarding to the preliminary estimated results, the Company has communicated with the accounting firm for annual audit and there is no disagreement among us. The preliminary estimated results have not been audited by the accounting firm.

III. EXPLANATION FOR THE CHANGES IN RESULTS

1. Impact of the principal business

During the year, the sales of the chemical drug preparation sector of the Company increased significantly, the sales in key advantageous areas such as gastroenterology, gonadotropic hormones and psychiatry achieved sustained and rapid growth as compared with the same period last year, combined with the steady increase in the proportion and profitability of high-end specialty APIs, which ensured the steady growth of the Company's overall performance.

2. Impact of the extraordinary gains or losses

In 2020, the Company disposed all of its equity interest in Jiangsu Ni Ke Medical Device Co., Ltd.* (江蘇尼科醫療器械有限公司), therefore the extraordinary gains or losses for 2021 decreased as compared with that of the previous year.

IV. RISK WARNING AND OTHER RELEVANT INFORMATION

- Figures related to these preliminary estimated results are arrived based on the estimated calculation of the Company, and have not been audited by the accounting firm;
- Detailed financial information will be disclosed in the 2021 Annual Report of the Company. Potential investors are advised to pay attention to the risks associated with the investment.

By order of the Board
麗珠醫藥集團股份有限公司
Livzon Pharmaceutical Group Inc.*
Yang Liang
Company Secretary

Zhuhai, China
14 January 2022

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman), Mr. Qiu Qingfeng and Mr. Yu Xiong; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Tian Qiusheng, Mr. Wong Kam Wa, Mr. Luo Huiyuan and Ms. Cui Lijie.

** For identification purpose only*